Category Archives: Stem Cell Treatment


HKUMed reveals pathogenic gene of carpal tunnel syndrome providing new directions for prevention and treatment – Mirage News

The LKS Faculty of Medicine of The University of Hong Kong (HKUMed), in collaboration with China-Japan Union Hospital of Jilin University, Mainland China, Harvard University and National Institutes of Health (NIH), U.S., have discovered that genetic mutation is one of the key risk factors of carpal tunnel syndrome (CTS). The study revealed a previously unrecognized mechanism in CTS pathogenesis and provided new insight into the development of new preventive and therapeutic strategies. The findings are now published in the leading multidisciplinary science journal Nature Communications [link to the publication].

Background

CTS, sometimes also known as mouse hand, is a fairly common condition in people, who have repeated and forceful movements of the hand and the wrist in their work and daily life, such as I.T. professionals, construction workers, cleaners and housewives. CTS is characterized by pain, numbness, tingling and weakness in the hand and the wrist due to excessive pressure on the median nerve within the carpal tunnel, which is often caused by swelling and thickening of soft connective tissues surrounding the median nerve.

CTS is a progressive disorder that can worsen without appropriate treatment, leading to nerve damage, permanent muscle atrophy, or loss of hand function. It is estimated to affect 1-5% of the general population[1] and is a leading cause of work disability. It is more common in people older than 40, and women are more likely to develop the condition than men; and more than one-half of cases will experience bilateral symptoms. According to the 0.1-0.3% incidence of CTS in U.S., the number of new cases in Hong Kong is estimated to be at least 7,000 per year[2].

In the past, most people believed that environmental factors, such as repetitive use of hands and wrists, were the main causes of CTS. However, familial occurrence of CTS in 1739% of cases[3] [4], a number of CTS families reported over the world and a large twin study that found an approximate 46% genetic contribution[5], suggest that genetic factors significantly influence CTS susceptibility. Nevertheless, so far, no causal genes were identified.

Research findings

It is challenging to study the pathogenesis of complex human diseases due to their multifactorial and polygenic nature, but Mendelian forms of common diseases have proven invaluable in identifying disease genes and elucidating pathogenic mechanisms. In this study, the research team analyzed two large pedigrees of CTS (nearly 100 cases) by using clinical, genetic, histological and biochemical methods. They discovered that mutations in a gene called COMP caused CTS in these two families.

COMP is highly expressed in the soft connective tissues surrounding the median nerve. The mutant COMP induced cellular stress response, leading to an accumulation of fibrotic and adipogenic cells. Eventually, fibrotic connective tissues in the human carpal tunnel become thickened and swollen, thus compressing the median nerve in causing CTS. Scientists further generated a CTS animal model, which recapitulated the progressive phenotype of human patients, and found that injury could significantly accelerate CTS onset.

Our findings provide solid evidence that genetic mutations can cause CTS, and COMP is the first identified causative gene. We also revealed cellular stress response as a novel mechanism underlying the pathogenesis of CTS, which lays the foundation for the future development of new treatments by inhibiting such response, said Dr Gao Bo, Assistant Professor of the School of Biomedical Sciences, HKUMed, who led the research.

The onset time and symptoms of familial patients are usually earlier and stronger than sporadic patients because the major risk factor is intrinsic (e.g. genetic) rather than extrinsic (e.g. life style, occupation). But sporadic CTS more likely result from combined effects of genetic susceptibility and environmental factors. When consulting a doctor, the patient should inform whether there are other affected members in his/her family, which will assist in diagnosis. I would also suggest, when introducing CTS to the public, the Hospital Authority should include genetic predisposition as one of the important risk factors of CTS, Dr Gao said.

About the Research Team

In collaboration with multiple institutions, the research was led by Dr Gao Bo, Assistant Professor of the School of Biomedical Sciences, HKUMed. Dr Li Chun-yu, China-Japan Union Hospital of Jilin University, Mainland China and Dr Wang Ni, Research Associate, School of Biomedical Sciences, HKUMed are co-first authors. Key international collaborators include Professor Yang Ying-zi, Harvard University, U.S.; Professor Cui Shu-sen, China-Japan Union Hospital of Jilin University, Mainland China and Dr Alejandro Schaffer, National Institutes of Health, U.S.. Other HKU scientists contributing to the research include Professor Danny Chan, S Y and H Y Cheng Professorship in Stem Cell Biology and Regenerative Medicine, Interim Director of School of Biomedical Sciences, HKUMed and Assistant Dean (Research postgraduate studies), HKUMed; Dr Wang Jin, Post-doctoral Fellow, School of Biomedical Sciences, HKUMed; Dr Wang Cheng, former Post-doctoral Fellow, School of Biomedical Sciences, HKUMed; and Ms Vanessa Choi Nga-ting, Technician, School of Biomedical Sciences, HKUMed.

The work was supported in part by Health and Medical Research Fund (Project #05160946) in Hong Kong.

The rest is here:
HKUMed reveals pathogenic gene of carpal tunnel syndrome providing new directions for prevention and treatment - Mirage News

Canine Stem Cell Therapy Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2019 2029 – Owned

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

This Press Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.xploremr.com/connectus/sample/2360

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Request Report Methodology at https://www.xploremr.com/connectus/request-methodology/2360

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Target Audience Production Companies Suppliers Channel Partners Marketing Authorities Subject Matter Experts Research Institutions Financial Institutions Market Consultants Government Authorities

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type: Allogeneic Stem Cells Autologous Stem cells

Application: Arthritis Dysplasia Tendonitis Lameness Others

End User: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Region: North America Latin America Europe Asia Pacific Japan Middle East & Africa

Buy Full Report at https://www.xploremr.com/cart/2360/SL

About Us

XploreMR, a leading market research firm, headquartered in San Jose, USA, XploreMR has, in a short span of time, served the market research needs of some of the biggest Fortune 500 companies. XploreMR also has highly personalized market research offerings for SMEs, and we pride ourselves on being uniquely positioned to have worked with colossal multinational firms and small, boutique firms. Our experience of working with such a diverse set from all over the world has given us invaluable perspectives on objectives, outlooks, goals, and eventually, the collective, symbiotic growth that stakeholders across the value chain aspire for. We keep these perspectives and aspirations in mind every time we work on a project, and this motivates us to exceed client expectations on a consistent basis.

Contact us: XploreMR 111 North Market Street, Suite 300, San Jose, CA 95113, United States Ph.No: +16692840108 E-mail id- [emailprotected] Web- https://www.xploremr.com

See the original post:
Canine Stem Cell Therapy Market Segment Analysis by Leading Players, Drivers, Regional, Competitive Landscape & Forecast To 2019 2029 - Owned

First-ever bone marrow transplant successfully conducted in UAE – WAM EN

ABU DHABI, 27th July, 2020 (WAM) -- In a landmark announcement of the first-ever bone marrow transplant successfully conducted in the UAE, Abu Dhabi Stem Cells Centre, ADSCC, today inaugurated the Abu Dhabi Bone Marrow Transplant programme, AD-BMT.

Typically used to treat patients with hematological and oncological illnesses, the bone marrow transplant was performed on a patient with multiple myeloma, a form of blood cancer. Though cancer is the third-highest cause of death in the UAE, Emirati citizens and residents have often sought treatment abroad for cell therapy and regenerative medicine.

The successful transplant, which was the result of collaboration between ADSCC and Sheikh Khalifa Medical City, represents a groundbreaking advancement for cancer patients living in the UAE who can now seek treatment closer to home to remain with family.

Bone marrow transplants, or hematopoietic stem cell transplantation, are one of the most established stem cell-based therapies in the treatment of cancer, particularly blood cancers. The unique treatment procedure developed by ADSCC, involved harvesting peripheral blood stem cells from the patient, who then underwent high-dose chemotherapy to eradicate all cancerous cells and most of the bone marrow. The harvested stem cells were then infused back into the bloodstream, where they restore the destroyed cells and over the course of two weeks restart the production of healthy non-malignant blood cells.

"The patient is basically without an immune system while waiting for the transfused cells to take effect and must remain in isolation under the strictest infection control guidelines," said Dr. Yendry Ventura, General Manager of ADSCC and BMT Programme Director. "Since we are still in the midst of a global pandemic, we took additional precautions to ensure the best outcome possible for all involved."

Earlier last month, ADSCC announced the results of the trial of its breakthrough treatment for COVID-19 patients, branded UAECell19, demonstrating its remarkable safety and efficacy. UAECell19 went on to secure three levels of intellectual property protection in recognition of its originality and novel medical application. Moreover, todays announcement of the Abu Dhabi Bone Marrow Transplant programme demonstrates ADSCCs continued commitment to delivering state-of-the-art and evidence-based services to the UAE market, including an array of stem cell therapies. It aims to make the BMT treatment available to all patients in the UAE who require it.

"It fills us with great pride to be part of a first for the country and to make such a life-saving treatment available and accessible to those who need it here," said Dr. Fatima Alkaabi, BMT Executive Director. "We are very grateful for the support and collaboration of SKMC in making this opportunity possible."

ADSCC was founded with the primary objective of meeting growing domestic and regional demand for advanced medical services and most innovative treatments in the UAE. ADSCC is committed to ensuring the Abu Dhabi Bone Marrow Transplant programme meets the highest standards of quality and patient satisfaction at all steps of the process, including treatment, aftercare, and follow-up between clinical BMT personnel, patients, and their families.

More here:
First-ever bone marrow transplant successfully conducted in UAE - WAM EN

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update – PRNewswire

NEW YORK, July 27, 2020 /PRNewswire/ --BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2020, and provide a corporate update, at 8:00 a.m., Eastern Daylight Time (EDT), on Wednesday, August 5 2020.

On the call, BrainStorm CEO Chaim Lebovits will present a corporate update, including details on the timeline for the data readout of the Company's Phase 3 pivotal trial studying the safety and efficacy of NurOwn (MSC-NTF cell) in people with ALS. In addition, Dr. Revital Aricha. Brainstorm's Vice President of Research and Development, will provide an R&D update including recently announced data from the Company's groundbreaking preclinical study evaluating NurOwn-derived exosomes for the treatment of COVID-19 ARDS.

Thereafter, senior management officers will join the call for a Q&A session. Participants are encouraged to submit their questions prior to the call by sending them to:[emailprotected]. Questions should be submitted by5:00 p.m. EDT,Monday, August 3, 2020.

Teleconference Details BRAINSTORM CELL THERAPEUTICS 2Q 2020

The investment community may participate in the conference call by dialing the following numbers:

Participant Numbers:

Toll Free: 877-407-9205 International: 201-689-8054

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors & Media" page of BrainStorm's website atwww.ir.brainstorm-cell.comand clicking on the conference call link.

Those that wish to listen to the replay of the conference call can do so by dialing the numbers below. The replay will be available for 14 days.

Replay Number:

Toll Free: 877-481-4010 International: 919-882-2331 Replay Passcode: 36017

Teleconference Replay Expiration:

Wednesday, August 19, 2020

About NurOwn

NurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors (NTFs). Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received acceptance from theU.S. Food and Drug Administration(FDA) to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS) and initiated enrollment inMarch 2019.

AboutBrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(FDA) and theEuropean Medicines Agency(EMA) for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at sixU.S.sites supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a filing forU.S.FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently receivedU.S.FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive multiple sclerosis (MS). The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment inMarch 2019. For more information, visit the company's website atwww.brainstorm-cell.com.

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Investor Relations:Preetam Shah, MBA, PhD Chief Financial Officer BrainStorm Cell Therapeutics Inc. Phone: +1-862-397-1860 [emailprotected]

Media:Paul Tyahla SmithSolve Phone: +1-973-713-3768 [emailprotected]

SOURCE Brainstorm Cell Therapeutics Inc

More here:
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update - PRNewswire

Stem Cell Therapy Market Research Outlook, Recent Trends and Growth Forecast 2020-2025 – Bulletin Line

The Stem Cell Therapy report provides independent information about the Stem Cell Therapy industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies profiles including business overview and recent development.

Stem Cell Therapy MarketLatest Research Report 2020:

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Stem Cell Therapy Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Stem Cell Therapy Market: Products in the Stem Cell Therapy classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Gilead,Novartis,Organogenesis,Vericel

Stem Cell Therapy Market Report Covers the Following Segments:

Product Type: Adult Stem Cells, Human Embryonic Stem Cells (hESC), Induced Pluripotent Stem Cells, Very Small Embryonic Like Stem Cells

Application: Regenerative Medicine, Drug Discovery and Development

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Stem Cell Therapy Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Stem Cell Therapy Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Stem Cell Therapy Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Stem Cell Therapy Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Stem Cell Therapy Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Stem Cell Therapy Market.

Market Forecast:Here, the report offers a complete forecast of the global Stem Cell Therapy Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/session-replay-software-market-2020-by-advanced-technologies-growth-opportunities-key-players-revenue-emerging-trends-and-business-strategy-till-2025-2020-04-24

https://www.marketwatch.com/press-release/session-replay-software-market-2020-by-advanced-technologies-growth-opportunities-key-players-revenue-emerging-trends-and-business-strategy-till-2025-2020-04-24

Top Trending Reports:

https://businessstatsnews.com/gan-micro-led-market-share-historical-growth-analysis-opportunities-and-forecast-to

https://teletype.in/@gunjanjadhav/cU1UNZMSt

https://technologyindustrynews.com/transfection-technologies-market-2020-by-advanced-technologies-growth-opportunities-key-players-revenue

https://businessstatsnews.com/portable-wheel-jack-market-global-industry-analysis-and-opportunity-assessment-2020-2025

https://businessstatsnews.com/global-blackcurrant-concentrate-market-size-growth-opportunity-and-forecast-to-2025

Go here to read the rest:
Stem Cell Therapy Market Research Outlook, Recent Trends and Growth Forecast 2020-2025 - Bulletin Line

Cell and Gene Therapy Tools, and Reagents: Global Markets – Yahoo Finance

NEW YORK, July 27, 2020 /PRNewswire/ -- Report Scope: The scope of this study encompasses an investigation of the markets cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors.The analyst examines each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years.

Read the full report: https://www.reportlinker.com/p05938974/?utm_source=PRN

Technological issues, including the latest trends, are discussed. The analyst examined the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

Report Includes: - 77 data tables - An overview of the global market for immunoassay-based cell and gene therapy tools, and reagents within the life sciences industry - Analyses of the global market trends, with data corresponding to market size for 2017-2019, and projections of compound annual growth rates (CAGRs) through 2024 - Information about in vitro diagnostics (IVD), its background and importance of IVD testing - Discussion on prevalence of infectious disease, metabolic disorders and chronic ailments as drivers of immunoassay testing market - Description of recent technologies such as chemiluminescent immunoassays (CLIA), fluorescent immunoassays, multiplex assays and rapid diagnostic technologies - Evaluation of market potential for immunoassay-based cell and gene therapy tools and reagents, current market size and market forecast, and market share analysis of the leading players engaged - Patent review and new developments, R&D efforts, industrial changes with emphasis on recent investments, and current state of the immunoassay technology - Company profiles of the key market participants, including Bio-Rad Laboratories, Cytiva Life Sciences, Luminex Corp., Millipore Sigma, Thermo Fisher Scientific and STEMCELL Technologies

Reasons for Doing this Study: Gene and cell therapy are emerging as important tools to treat human health.Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers.

The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene- based diseases.As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging.

This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

Read the full report: https://www.reportlinker.com/p05938974/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/cell-and-gene-therapy-tools-and-reagents-global-markets-301100062.html

SOURCE Reportlinker

Go here to read the rest:
Cell and Gene Therapy Tools, and Reagents: Global Markets - Yahoo Finance

R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico – PR Web

Stem Cell Therapy for Back Pain in Mexico (888) 988-0515

SCOTTSDALE, Ariz. (PRWEB) July 27, 2020

The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

With close to 9 out of 10 experiencing significant back pain at some point in life, there are millions of individuals who deal with back pain every day. It may be incapacitating, with traditional treatment options often not working exceptionally well. This may include risky narcotics or surgery.

According to R3 CEO David Greene, MD, MBA, "Chronic back pain dampens quality of life, with patients often not being able to work or play with their kids or grandkids. Stem cell treatment with R3 in Mexico is a fantastically effective option for those who want to eliminate pain without surgery or narcotics. It starts at only $2975 too!"

Stem cell therapy for back pain in Mexico at R3 International provides a safe, effective option for patients to alleviate back pain without surgery. Depending on the patient's reason for back pain, treatment may be provided IV, injection, intrathecal or with a combination. Each individual undergoes a free consultation with one of R3's licensed, experienced stem cell doctors who will review medical records and make the treatment suggestion.

Patient satisfaction at R3 Stem Cell International exceeds 87% overall, with treatments being offered for back pain, joint arthritis, Lyme disease, kidney failure, COPD, stroke, neuropathy, Alzheimers, diabetes, Crohns and more. Patients receive an escort from San Diego to the Tijuana clinic, which is only 20 minutes away along with an escort to the treatment and back.

To get set up for a free phone consultation, call (888) 988-0515 and visit https://stemcelltreatmentclinic.com for more information.

Share article on social media or email:

Originally posted here:
R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico - PR Web

Team led by Manchester Scientists discover a way to slow the growth of breast cancer stem cells – About Manchester – About Manchester

A team of British and American scientists have discovered a way to slow the growth of breast cancer stem cells in the lab.

The study led by Dr Bruno Simes and Professor Rob Clarke from The University of Manchester could eventually lead to combination drug therapies on previously untreatable breast cancers.

Around three quarters of women who have breast cancer have what are known as oestrogen receptor positive tumours.

Some breast cancer cells have receptors that bind to the hormone oestrogen and depend on it to grow.

Though anti-oestrogen drugs such as tamoxifen and fulvestrant are able to prevent reoccurrence in most of these breast cancers, tumours reoccur in 1 out of 4 cases.

Many of the women relapse after several years, because some of the cancer cells remain after treatment.

The cells, called cancer stem cells, lay dormant in the body and cannot be targeted by anti-oestrogen therapies.

Scientists have now found that cancer stem cells resistant to anti-oestrogen drugs express an immune system-related receptor called interleukin 1 receptor.

The team found that a biological inhibitor of this receptor called Anakinra, used to treat rheumatoid arthritis, was able to reduce the ability of the cancer stem cells to form colonies in vitro.

However, further validation in animals and humans is required before the team to confirm if drugs targeting interleukin 1 receptor could be used as an effective treatment.

The study, published in Stem Cell Reports was funded by the Medical Research Council and Breast Cancer Now.

Scientists from the Universities of Michigan, Liverpool and Edinburgh were closely involved in the work from the team in Manchester.

Dr Simes said: Resistance to anti-oestrogen therapies in breast cancer patients is a major problem and one which cancer scientists have been trying to address for many years.

Many drugs have been investigated by scientists as a possible combination therapy taken with anti-oestrogen therapies and we are still searching for a solution for these patients.

However, most of these drugs target actively dividing cells whereas we are trying to also target cells that are in a dormant state.

So we hope that these women who have increased numbers of cancer stem cells and do not respond to currents treatment could one day benefit from combination therapy.

Theres a very long way to go before we can say if this approach will help these women but we are excited by our findings.

Continue reading here:
Team led by Manchester Scientists discover a way to slow the growth of breast cancer stem cells - About Manchester - About Manchester

R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico – Yahoo Finance

The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

SCOTTSDALE, Ariz., July 27, 2020 /PRNewswire-PRWeb/ -- The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

With close to 9 out of 10 experiencing significant back pain at some point in life, there are millions of individuals who deal with back pain every day. It may be incapacitating, with traditional treatment options often not working exceptionally well. This may include risky narcotics or surgery.

According to R3 CEO David Greene, MD, MBA, "Chronic back pain dampens quality of life, with patients often not being able to work or play with their kids or grandkids. Stem cell treatment with R3 in Mexico is a fantastically effective option for those who want to eliminate pain without surgery or narcotics. It starts at only $2975 too!"

Stem cell therapy for back pain in Mexico at R3 International provides a safe, effective option for patients to alleviate back pain without surgery. Depending on the patient's reason for back pain, treatment may be provided IV, injection, intrathecal or with a combination. Each individual undergoes a free consultation with one of R3's licensed, experienced stem cell doctors who will review medical records and make the treatment suggestion.

Patient satisfaction at R3 Stem Cell International exceeds 87% overall, with treatments being offered for back pain, joint arthritis, Lyme disease, kidney failure, COPD, stroke, neuropathy, Alzheimers, diabetes, Crohns and more. Patients receive an escort from San Diego to the Tijuana clinic, which is only 20 minutes away along with an escort to the treatment and back.

To get set up for a free phone consultation, call (888) 988-0515 and visit https://stemcelltreatmentclinic.com for more information.

SOURCE R3 Stem Cell International

Read the original:
R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico - Yahoo Finance

Cell Therapy Instrument Market IN COVID-19: IMPLICATIONS AND BUSINESS OPPORTUNITIES FOR GROWTH GLOBALLY – Owned

The Cell Therapy Instrument Market report has been recently added by Report Ocean to its vast repository. This intelligence report includes investigations based on Historical records, Current scenarios, and future predictions. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Cell Therapy Instrument Market is showing steady growth and CAGR is expected to improve during the forecast period.

The Cell Therapy Instrument Market Research Report categorizes the Cell Therapy Instrument Market by key players, product type, applications, and regions, etc. The report also covers the latest industry data, key players analysis, market share, growth rate, opportunities and trends, investment strategy for your reference in analyzing the Cell Therapy Instrument Market.

COVID- 19 Impact on Cell Therapy Instrument Market

As companies move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on strategies that may result in emerging as strong market player. This market research report included the detailed study related to impact of COVID-19 on the supply chain based on both downstream and upstream markets. The report also includes the future development in the Cell Therapy Instrument Market in relation with the impact of COVID-19 on the market.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=bis64080

Competitive Landscape:

This section of the report has mainly focused on Key Strategies adopted by leading players in Cell Therapy Instrument Market. These companies are selected based on revenue, innovations, strength of product portfolio, regional presence, investment capacity and similar other factors.

BD Bioscience Danaher (Beckman Coulter, Inc.) General Electric Lonza Merck Kgaa Miltenyi Biotec Sartorius AG Stemcell Technologies Inc. Terumo Corporation Thermo Fisher Scientific Inc.

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Cell Therapy Instrument Market.

Product Type Segmentation Human Cells Animal Cells

Industry Segmentation Cell Processing Cell Preservation Distribution & Handling Process Monitoring & Quality Control

Channel (Direct Sales, Distributor) Segmentation

Region Segmentation:

Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in Cell Therapy Instrument Market. The regional analysis section of the report offers an extensive analysis of the Cell Therapy Instrument Market based on region. The Cell Therapy Instrument Market will showcase a steady CAGR in the forecast year.

Unravelling the geographical landscape of the Cell Therapy Instrument Market:

Americas (United States, Canada, Mexico, Brazil)

APAC (China, Japan, Korea, Southeast Asia, India, Australia)

Europe (Germany, France, UK, Italy, Russia, Spain)

Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Some of the Points cover in Cell Therapy Instrument Market Research Report are:

Chapter 1: Overview of Cell Therapy Instrument Market

Definition

Specifications

Classification

Applications

Regions

Chapter 2: Market Competition by Players/Suppliers

Manufacturing Cost Structure

Raw Material and Suppliers

Manufacturing Process

Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region

Sales

Revenue and market share

Chapter 4, 5 and 6: Cell Therapy Instrument Market by Type, Application & Players/Suppliers Profiles

Market Share by Type & Application

Growth Rate by Type & Application

Drivers and Opportunities

Company Basic Information

Continued

Note: Regional Breakdown & Sectional purchase Available We provide Pie chats Best Customize Reports As per Requirements.

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=bis64080

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US) Contact Person: Tom Email:[emailprotected]

Link:
Cell Therapy Instrument Market IN COVID-19: IMPLICATIONS AND BUSINESS OPPORTUNITIES FOR GROWTH GLOBALLY - Owned